Antipsychotic long-acting injections: Mind the gap

British Journal of Psychiatry

Volumn 195, Issue SUPPL. 52, 2009, Pages

  Patel, Maxine X ^a   Taylor, Mark ^b   David, Anthony S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Ballenden House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSYCHOTIC LONG ACTING INJECTION AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

DRUG COST; DRUG FORMULATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; REVIEW; SCHIZOPHRENIA; DELAYED RELEASE FORMULATION; EDITORIAL; INJECTION;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 71249142333     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.195.52.s1     Document Type: Review

References (46)

1. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773
2. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often, and what can be done about it? Advan Psychiatr Treat 2005; 11: 203-213
3. Johnson DAW. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry 2009; 195 (suppl 52): s7-12.
4. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trial and observational studies. Br J Psychiatry 2009; 195 (suppl 52): s20-8.
5. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247 (Pubitemid 29125132)
6. Barnes TRE, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry 2009; 195 (suppl 52): s37-42.
7. Miles CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977; 164: 231-246
8. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia. Arch Gen Psychiatry 2005; 62: 247-253
9. Fleischhacker WW. second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195 (suppl 52): s29-36.
10. Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6: 367-381
11. Johnson DAW, Wright NF. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990; 156: 827-834
12. Shah AK. Prescribing patterns in a psychiatric follow-up clinic. Psychiatr Bull 1991; 15: 484-485
13. Galletly CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust N Z J Psychiatry 1992; 26: 574-576
14. Barnes TRE, Curson DA. Long-acting depot antipsychotics: a risk-benefit assessment. Drug Saf 1994; 10: 464-479
15. Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry 2000; 8: 220-224 (Pubitemid 30802023)
16. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196-201. (Pubitemid 28071427)
17. Pinikahana J, Happell B, Taylor M, Keks NA. Exploring the complexity of compliance in schizophrenia. Issues Ment Health Nurs 2002; 23: 5123-5128
18. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159: 1653-1664
19. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia. A retrospective review. J Clin Psychiatry 2006; 67: 1542-1550 (Pubitemid 44787436)
20. Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry 1995; 49 (suppl 35): 41-46
21. Levine J, Schooler NR, Cassano GB. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol Med 1979; 9: 383-386 (Pubitemid 9198807)
22. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14: 105-122 (Pubitemid 17222209)
23. Young JL, Spitz RT, Hillbrand M, Danieri G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. J Am Acad Psychiatry Law 1999; 27: 426-444 (Pubitemid 29467839)
24. Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998; 49: 1232-1234
25. Tattan TMG, Creed FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001; 27: 149-155 (Pubitemid 32199270)
26. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Serv 2007; 58: 482-488 (Pubitemid 46640638)
27. Paton C, Barnes TRE, Cavanagh MR, Taylor D, Lelliott P, the POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK; the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435-439 (Pubitemid 351809896)
28. Barnes TRE, Paton C, Cavanagh MR, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397-1401
29. Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118: 26-33. (Pubitemid 351832021)
30. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195 (suppl 52): s43-50.
31. Gray R, Spilling R, Burgess D, Newey T. Antipsychotic long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry 2009; 195 (suppl 52): s51-6.
32. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8: 55-66. (Pubitemid 28012861)
33. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89 (Pubitemid 36113403)
34. Glazer WM. The depot paradox. Behav Healthcare 2007; 27: 44-46
35. Adams CE, Fenton MKP, Quraishi S, David AS. Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299 (Pubitemid 32996037)
36. Lieberman JA, Stroup S, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223 (Pubitemid 41345943)
37. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of effect on quality of life of second- vs first- generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087
38. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPW, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-1097
39. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections. Br J Psychiatry 2009; 195 (suppl 52): s13-9.
40. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomised controlled trials. Schizophr Bull 2009; 35: 443-457
41. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135-145 (Pubitemid 30386882)
42. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564 (Pubitemid 36682312)
43. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006; 67: 1948-1953 (Pubitemid 46048193)
44. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009; 195 (suppl 52): s63-7.
45. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). Clinical Guideline CG82. NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/CG82NICEGuideline.pdf).
46. Lambert TJ, Singh BS, Patel MX. Community treatment orders and antipsychotic long-acting injections. Br J Psychiatry 2009; 195 (suppl 52): s57-62.